On this US Labor Day, I feel gratitude for the many dedicated @UNC_Health_Care and @UNC_Lineberger staff supporting patients with cancer, particularly after 2+ tough years with staffing shortages and Covid absences. Thank you.
English
Ethan Basch
320 posts
Ethan Basch
@EthanBasch1
Oncologist, Cancer Outcomes Researcher, Bass Player
Katılım Mayıs 2014
115 Takip Edilen1.9K Takipçiler
Ethan Basch retweetledi
New models of working for #clinical trials? Patient-informed investigator reporting of adverse events @EthanBasch1 @BiostatGirl #OCEoutcomes22 @FDAOncology - love this approach! @NIHRBhamBRC
English
Ethan Basch retweetledi
Great to see this impt work out in JAMA & honored to contribute on behalf of @ASCO. Congrats to @EthanBasch1 & all co-authors 👉🏻 Electronic Symptom Monitoring With Patient-Reported Surveys and Outcomes Among Patients With Metastatic Cancer ja.ma/3zo2cK3 #PRO #HRQOL
English
Ethan Basch retweetledi
Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic #Cancer.
jamanetwork.com/journals/jama/…
@ASCO @JAMA_current @EthanBasch1 @BiostatGirl
#PallOnc #PROs #DigitalHealth #ASCO22
English
Ethan Basch retweetledi
#ASCO22 TOMORROW: Join presenters from the #ASCOPlenarySeries for ⚡ rapid abstract updates on their research, followed by a panel q&a moderated by @GeorgeSledge51 & @KimmieNgMD
📅 6/5, 4:30 – 6:00 PM CT
📌 Arie Crown Theater & Online
@EthanBasch1 @GistLab @ProfGLongMIA
English
Excited to present at #ASCO22, the PRO-TECT multicenter randomized trial of a PRO digital tool for symptom monitoring in US oncology practices, with simultaneous publication in JAMA @JAMA_current, in the ASCO Plenary Series update session, 6/5/22 5:30pm EDT. @ALLIANCE_org @PCORI
English
@drmelcalvert @JAMA_current The pleasure was all mine! Many thanks Dr. Calvert for this superb work.
English
Thanks for sharing Shamil. It was a pleasure to record this podcast to accompany our PRO ethics guidelines in @JAMA_current jamanetwork.com/journals/jama/… Always great chatting to my brilliant friend and collaborator @EthanBasch1! Hopefully next time in person!
Shamil Haroon@ShamilHaroon
English
Ethan Basch retweetledi
Our pre-preprint has been uploaded (free available from the URL below). It will be come out as a preprint (and hopefully a peer-reviewed paper) pretty soon.
And yes, we are G2P-Japan🇯🇵
Happy Xmas🎄 5/5
drive.google.com/file/d/1rhCazF…
English
Ethan Basch retweetledi
Moreover, our statistical analysis shows that Omicron is >3-5-fold more transmissible than Delta. 4/5
English
Ethan Basch retweetledi
In sharp contrast, Omicron is less fusogenic (left panel) and its spike is faintly cleaved (right panel). Our data suggest that the efficacy of spike protein cleavage, fusogenicity and pathogenicity are well correlated each other. 3/5
English
Ethan Basch retweetledi
How come?
We have recently reported that Delta spike is efficiently cleaved into two subunits, and therefore, Delta is highly fusogenic and highly pathogenic @Nature . 2/5
nature.com/articles/s4158…
English
Ethan Basch retweetledi
Ethan Basch retweetledi
New #COVID19 🦠 #openaccess resource in Annals of Oncology: COVID-19 Vaccination 💉 and Breakthrough Infections in Patients with Cancer
➡️ annalsofoncology.org/article/S0923-…
@COVID19nCCC @DrChoueiri
English
Ethan Basch retweetledi
Adolescent and young adult patients w/ #cancer are well-represented in @theNCI #ClinicalTrials and are more racially/ethnically diverse than older patients acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @SWOG @fredhutch @DrJoeUnger @DrDawnHershman
English
Ethan Basch retweetledi
News from #ASCOPlenarySeries: Digital Symptom Monitoring With PROs in Community Practices Improves Patient QoL via @TargetedOnc @Sara_Karlo7 fal.cn/3jWkz @EthanBasch1 #medtech #digitalhealth #ePROs
English
Ethan Basch retweetledi
Looking forward for the inaugural #ASCOPlenarySeries from @EthanBasch1 @UNC_Lineberger -Digital symptoms monitoring in the oncology community: a randomized trial! @ASCO @ASCOPres @jrgralow @CliffordHudis @MLJohnsonMD2 @GeorgeSledge51
ASCO@ASCO
.@EthanBasch1 of @UNC_Lineberger to present #ASCOPlenarySeries Abstract 349527: Digital symptom monitoring w/ PROs in community oncology practices: A US nat'l cluster randomized trial. Join us 11/16 @ 3 PM EST for presentation, discussion and Q&A ➡️ fal.cn/3jOQI
English
Ethan Basch retweetledi
Nice to collaborate w/@gitamody on this impt paper! ePRO monitoring during lung cancer tx not only feasible but identified severe sxs lungcancerjournal.info/article/S0169-… @Angela_M_Stover @angiesmith_uro @EthanBasch1 @arlenechung @bennettphd @BiostatGirl @debschrag @BellKingKal
English
@MassimoDiMaio75 @BiostatGirl @drmelcalvert @marialuciareale Agree @MassimoDiMaio75 — here’s an example of such an analysis jamanetwork.com/journals/jamao…
English
@BiostatGirl @drmelcalvert I agree with you. A strong and elegant further demonstration would be the absence of difference between open label trials and blinded trials with the same question (as suggested some time ago by @marialuciareale) but too few studies are actually eligible for that comparison
English
Great paper & thread! This is a standard criticism made against PROs, so extremely important to have data to put this to rest! PROs are hard outcomes & arguably some of the strongest biomarkers available IMHO. Great work Fabio Efficace, @drmelcalvert, @MassimoDiMaio75, et al!
EORTC QLG Early Career Investigators@EORTC_QLG_ECI
There are some concerns on how blinding in #randomizedclinicaltrials #RCTs (ie, if patients/investigators know which treatment they are receiving) influences patient-reported outcomes (#PRO)🧐 A new review by Fabio Efficace et al looked into this issue🧵 ogy.de/e405
English
@BiostatGirl @drmelcalvert @MassimoDiMaio75 This is an important paper for PRO use in cancer drug development, laying to rest the fallacy that unblinding of treatment allocation in controlled or single arm trials affects PRO responses - it DOESN’T. Key for @FDAOncology to acknowledge and encourage PROs in all applications.
English
Ethan Basch retweetledi
Just kicked this years workshop off and excited to hear @vishalbmd and @EGHorod lead some interesting sessions on physical function! How can we analyze and describe physical function for patients receiving an anti-cancer treatment? #OCEOutcomes21
FDA Oncology@FDAOncology
Happening now! COA-CCT Session 1, moderator OCE Associate Director for Patient Outcomes Vishal Bhatnagar @vishalbmd discussing physical function endpoints in trials with @paspears88 @MallorieFiero @EthanBasch1 Lori Minasian & Peter Trask #OCEOutcomes21 bit.ly/2Sjhm0d
English